Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SANGUINE CORP. (SGNC) -- Ignore unavailable to you. Want to Upgrade?

To: CrazyTrain who wrote (4395)	10/17/1998 6:11:00 PM
From: Mr. Forthright	Respond to of 5402

Why don't you ask Prospector what I meant. He knows...

To: CrazyTrain who wrote (4395)	10/17/1998 7:24:00 PM
From: Prospector	Respond to of 5402

Tokyo Japan world conference Dr. Dave Long at Long labs began work on fluorocarbons for imaging in material 30 years ago, and when that did not work, they in 1993 (under the new name Alliance Pharmaceuticals) switched to synthetic red cells made from perfluorooctyl bromide in 1993. In the late 1960s, United States professors Clark, Geyer and Sloviter began work on fluorocarbons (PFC) for synthetic red blood cells. Green Cross Corp. Osaka, Japan, assumed the rights to their U.S. invention when the three professors were unable NIH funding due to American Red Cross opposition at NIH. to a product that competed with donor blood. Green Cross and its U.S. subsidiary Alpha Therapeutic Corp. Los Angeles, began clinical trials in 1979 and obtained a U.S. FDA license in 1989 for Fluosol DA-20% for PCTA (angioplasty). Somatogen dropped out of the gene machinery manufacturing business and 1980s and began research on the production of red blood cells from recombinant DNA. There are a few other contenders including Sanguine BioPure (bovine),Synthetic Blood and Apex Bioscience Hemosol (fresenius, and Enson. Dropouts include Abbott Upjohn, Lilly Synthetic Blood Inc. U.S. Army in Navy Adamantech, Affinity Biotech, Sun Tech, Oxygentics, DNX, Hemagen Burns Labs, Pharmacia, Quest and others. Aside from Pharmacia, Kabi, and fresenius, there has been surprisingly little interest in Europe or Japan, with the exception Ajinomoto. Green Cross was cut because of falsifying the date on in early patient clinical trial was forced to withdraw its data in Japan for three years. Alpha, Green Cross, U.S. subsidiary continued its U.S. FDA trials. Green Cross banker management Dr. Naito died, lost interest and dropped out in 1993 after getting the only FDA license in 1989. China and Russia have made copies of the green cross product but do not do much with them. The other competitors continue to have recurrent development problems, which alpha never experienced. COMMERCIAL ANALYST OF BLOOD SUBSTITUTES: Most drug company experts that have been interviewed, state that synthetic red blood sales will be the largest pharmaceutical market of all-time. Most drugs have one or to label claims or indications but synthetic blood will have dozens of them because its goals are to reduce ischemia and hypoxia,, anywhere it happens in the body, unlike other pharmaceuticals which attack bacteria, viruses or disease. Oxygen is the most vital chemical in the body, so an oxygen shortage is life-threatening wherever and whenever it occurs. The largest market is transfusion, with at least 60 million transfusions performed worldwide each year. The Who in Geneva states that this market could grow to 120 million to 180 million transfusions per year if there were a manufactured blood cell since difficulties of collecting donated red blood cells, the need for donors, and venereal disease and viral testing hepatitis B and C AIDS, typing in cross matching, refrigeration and short-shelf would be eliminated. Hemodilution is part of the transfusion market. The next largest markets are the three biggest killers in the United States heart attack, cancer and stroke. None of these presently use blood to cure or relieve the disease. In cardiology, synthetic blood will be used in cardioplegia to prime the heart-lung pump for a open heart surgery. It may also be used relieve clot in myocardial in fraction and has been license for angioplasty by the FDA and use successfully for thousands of patients. Incidentally, under the angioplasty label, hundreds inserted surgery patients especially Jehovah's witnesses who refuse blood were transfused with Fluosol Alpha by a Dr. Richard Spence and others. to be continued Prospector